A controlled, randomized, open-label study to evaluate the effects of every-2-week darbepoetin alfa for anemia of cancer

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 12-13

  Charu, Veena ^a   Belani, Chandra ^a   Gill, Ahmad ^a   Bhatt, Mukesh ^a   Ben Jacob, Ali ^a   Tomita, Dianne ^a   Katz, Danica ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; KIDNEY FUNCTION; LENGTH OF STAY; LIVER FUNCTION; LUNG CANCER; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPEN STUDY; PROGNOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 15944406371     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Charu V, Belani C, Gill A, et al. A controlled, randomized, open-label study to evaluate the effects of every-2-week darbepoetin alfa for anemia of cancer. Poster presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 8084.